PPAG RSS Feed

21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference on 18-Apr-12 8:00 AM

Wed, 18 Apr 2012 13:00:00 GMT

21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference
Start Date: 18-Apr-12 8:00 AM
End Time: 22-Apr-12 12:30 PM
Location: Houston Marriott at the Texas Medical Center, Houston, TX 77030
Event Details:

The 21st PPAG Annual Meeting and 2012 Pediatric Pharmacy Conference is designed for practitioners and administrators involved in drug therapy decisions for children. The Conference is designed by pediatric pharmacists who understand the unique needs of the pediatric patient. This conference will provide important educational benefits for participants who want to improve their positioning in the health care enviornment. It will also provide a new understanding of current medical and clinical trends in pediatric health care. The overall conference goals are as follows: Provide and review current information and developments pertaining to pediatric medication use in infectious diseases. Review new technologies that can reduce the risk of errors in the pediatric population. Discuss new drugs on the market and their application to pediatric patient care. Provide a forum for the exchange of information and ideas among pediatric practitioners. Review and discuss clinical leadership and management in the pediatric pharmacy setting. The 21st Annual PPAG Conference features two educational blocks. The Infectious Diseases Block will is offered April 18-20, 2012 and the Clinical Leadership and Management Block will be held from April 20-22, 2012. Participants can participate in both blocks.
Conference Agenda Information Educational Agenda Infectious Diseases Educational Block Clinical Leadership and Management Block Both Blocks Educational Learning Objectives (coming soon). Call For Abstracts The Research and Advocacy Committee invite you to submit your scientific and practice-based abstracts. For more information, please see our Call for Abstracts.	Registration Information and Policy Participants may participate in one or both educational blocks. Early bird discounts will be offered through February 17, 2012. Refunds will be given through March 16, 2012. After March 16, 2012 no refunds will be given, but balances can be transferred to future conferences. Pre-registration will end April 11, 2012. Onsite registration is available after April 11, 2012. To register online, click here. To register via mail or fax, click here.
Hotel Information-- Affordable Rates! The Marriott Houston at the Texas Medical Center has been chosen as the official hotel of the 21st PPAG Annual Meeting and Pediatric Pharmacy Conference. PPAG has secured a room-rate of $139.00 per night. Individual attendees are responsible for making their own hotel reservations. You can make reservations by calling 1-713-796-0080. You can also make your reservations online. You must indicate that you are attending the "PPAG Pediatric" event. The online group code is PPAPPAA Click here to make your reservations online. Reservations must be made on or before Tuesday, April 10, 2012.	About Houston, Texas For more information about Houston, pleae visit the Greater Houston Convention and Visitor Bureau website.
The Pediatric Pharmacy Advocacy Group is an approved by the Accrediting Council of Pharmacy Education as a provider of pharmacy education. The 21st Annual PPAG Meeting and Pediatric Pharmacy Conference offers up to 28 continuing educational contact hours. To receive credit participants must attend the session and fill out the online verification of attendance and conference evaluation form. Certificates will be send 3-4 weeks after the completion of the conference. Participants will not receive credit if there is a balance due on their account. PPAG will disclose any financial support received from the pharmaceutical industry during the conference. The PPAG Education Committee makes substantial effort to present conference materials in an unbiased manner. PPAG educational programming is 100% supported by registration and member fees. Any grievance should be sent directly to the PPAG Executive Director.

Houston Marriott at the Texas Medical Center

6580 Fannin Street

Houston, TX USA 77030

22nd Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference on 1-May-13 8:30 AM

Wed, 01 May 2013 13:30:00 GMT

22nd Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference
Start Date: 1-May-13 8:30 AM
End Time: 5-May-13 5:30 PM
Location: Indianapolis Marriott Downtown, Indianapolis, IN 46225
Event Details:

The 22nd PPAG Annual Meeting and 2013 Pediatric Pharmacy Conference is designed for practitioners and administrators involved in drug therapy decisions for children. The Conference is designed by pediatric pharmacists who understand the unique needs of the pediatric patient. This conference will provide important educational benefits for participants who want to improve their positioning in the health care enviornment. It will also provide a new understanding of current medical and clinical trends in pediatric health care. The overall conference goals are as follows: Provide and review current information and developments pertaining to pediatric medication use in neonatal and pediatric critical care. Review new technologies that can reduce the risk of errors in the pediatric population. Discuss new drugs on the market and their application to pediatric patient care. Provide a forum for the exchange of information and ideas among pediatric practitioners. The 22nd Annual PPAG Conference features two educational blocks. The Pediatric Critical Care Block will is offered May 1-3, 2013 and the Neonatal Critical Care Block will be held from May 3-5, 2013. Participants can participate in both blocks.
Conference Agenda Information TBA Call For Abstracts TBA	Registration Information and Policy TBA
Hotel Information-- Affordable Rates! The Indianapolis Marriott Downtown has been chosen as the official hotel of the 22st PPAG Annual Meeting and 2013 Pediatric Pharmacy Conference. PPAG has secured a room-rate of $155.00 per night. Individual attendees are responsible for making their own hotel reservations. You can make reservations by calling 1-800-266-9432. You can also make your reservations online. You must indicate that you are attending the "PPAG Pediatric" event. Reservations must be made on or before Sunday, March 31, 2013.	About Indianapolis, IN For more information about Indianapolis, pleae visit the Visit Indianapolis website: http://visitindy.com/
The Pediatric Pharmacy Advocacy Group is an approved by the Accrediting Council of Pharmacy Education as a provider of pharmacy education. The 22st Annual PPAG Meeting and Pediatric Pharmacy Conference offers up to 28 continuing educational contact hours. To receive credit participants must attend the session and fill out the online verification of attendance and conference evaluation form. Certificates will be send 3-4 weeks after the completion of the conference. Participants will not receive credit if there is a balance due on their account. PPAG will disclose any financial support received from the pharmaceutical industry during the conference. The PPAG Education Committee makes substantial effort to present conference materials in an unbiased manner. PPAG educational programming is 100% supported by registration and member fees. Any grievance should be sent directly to the PPAG Executive Director.

Indianapolis Marriott Downtown

350 West Maryland Street

Indianapolis, IN US 46225

PPAG Joins Coalition for BCPA/PREA

Matthew Helms - noemail@ppag.org — Fri, 03 Feb 2012 18:00:00 GMT

PPAG recently joined seven other organizations (The American Academy of Child and Adolescent Psychiatry, the American Academy of Pediatrics, the American Society of Pediatric Nephrology, the American Thoracic Society, the Elizabeth Glaser Pediatric AIDS Foundation, and the March of Dimes) who support the reauthorization of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA).

BPCA and PREA: An Overview

Children are not just small adults. Drugs work differently in children than in adults and must be studied specifically for their use.

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) are two laws that encourage and require the study of drugs in children. Data resulting from BPCA and PREA studies are added to drug labels to give parents and providers essential information on the safety and efficacy of drugs used in children.

PREA requires drug companies to study adult drug indications in children when the product is likely to be used in a significant number of children or represents a meaningful therapeutic benefit over existing therapies. While PREA is a requirement, it cannot delay access to the adult version of the product.

BPCA is an incentive for drug companies to conduct FDA-requested pediatric studies—especially for off-label drug uses—in return for an additional six months of marketing exclusivity.

A Track Record of Success

BPCA and PREA have changed pediatric practice because all studies result in labeling changes that provide valuable new pediatric information. These studies have resulted in new dosing information, new indications of use, new safety information, and new data on effectiveness. Drugs studied under BPCA and PREA treat a wide range of diseases in children, including cancer, HIV/AIDS, diabetes, allergy and asthma.

426 drug labels have been revised with important pediatric information (181 under PREA, 147 under BPCA, 50 under both BPCA and PREA, and 48 under precursor regulations).

Before BPCA and PREA, the vast majority of drugs—more than 80%—used in children were used off-label, without data on their safety or efficacy. Today that number has been reduced to approximately 50%. While there has been significant success, more progress is needed.

Priorities for Reauthorization

Reauthorize these important laws. BPCA and PREA expire on October 1, 2012. These laws must be reauthorized to continue these important advances for children. PREA should be made permanent law—basic safety and efficacy provisions for adults do not expire and they should not for children. In addition, the program that funds the study of older off-patent drugs at the National Institutes of Health (NIH) should also be reauthorized.

Plan pediatric studies earlier. The precursor to PREA, the Pediatric Rule, required that drug companies discuss and plan for pediatric studies no later than the end of phase 2. Since PREA replaced the Pediatric Rule, the pediatric plan submission under PREA cannot occur until the time a company submits its drug application. This can lead to insufficient and inappropriate study plans and delays of important pediatric data. Drug companies should begin discussions with FDA at the end of phase 2 of the drug development process, similar to the Pediatric Rule.

Improve accountability. PREA studies can be waived or deferred to a later time post-market. Deadlines for deferred studies, however, are missed a vast majority of the time. Of all deferred PREA studies due after September 27, 2007, an alarming 78% are currently late or were submitted late. The FDA should distinguish between reasonable and unreasonable delays and have enforcement tools comparable to those for post-market requirements in adults to ensure that pediatric data is gathered as soon as possible.

Promote studies in younger age groups. Studying drugs in neonates—the smallest children—is very difficult. The GAO found that FDA lacks neonatal expertise. Increase neonatal expertise at FDA and encourage additional discussion of neonates and younger age groups.

Increase transparency. Pediatric researchers cannot access information on what drugs are currently being studied under BPCA. BPCA study requests declined by drug companies—evidence of important gaps in pediatric data—are never made public. Some pediatric data submitted prior to 2007 has also not been made public. Improve transparency provisions to increase access to important pediatric information.

Special thanks to the American Academy of Pediatrics for their assistance authoring this article.

3-Feb-12 12:00 PM

PPAG Endorses Drug Shortages Prevention Act: Call to Action

Matthew Helms - noemail@ppag.org — Thu, 02 Feb 2012 21:30:00 GMT

On February 1, 2012, U.S. Representatives John Carney (D-DE) and Larry Bucshon (R-IN) introduced the Drug Shortage Prevention Act to address the scarcity of certain pharmaceutical drugs in the marketplace.

PPAG members and other healthcare professionals have been dealing with drug shortages for well over a year. Last September, PPAG leadership participated in the FDA's National Drug Shortage Summit, where healthcare leaders deemed the drug shortage problem a national healthcare crisis.

The new legislation (H.R.3839), which PPAG endorses, mandates expedited review of drugs vulnerable to shortage in order to prevent shortages in the first place and it requires the FDA to use a more refined regulatory process that addresses manufacturing problems without instigating drug shortages. Two additional bills, S. 296 entitled "Preserving Access to Life Saving Medications Act" and its companion bill, H.R. 2245 "Preserving Access to Life-Saving Medications Act of 2011" were introduced last year.

PPAG members and constituents are encouraged to contact their legislators to express support for these bills. Together we can really make a difference with this issue.

Please take the time to write to your legislator today and spread the word to your colleagues and friends.

To find and write your elected officials, follow the step-by-step directions below:

Visit http://www.congress.org
Enter your 9-digit zip code
Click on the elected official
Click on "contact," then "web form.
Insert your letter and submit.

Here is a sample letter of support for the legislation.

Tips for a good letter to your elected officials:

Make in personal- tell them who you are.
Make it short.
Stay on point- address only one issue.
Cite a specific bill - by number if possible.
Send the letter by mail.
Send it to your legislators only. Put your home address and zip code in your letter. (Many legislators will only accept mail and email from their own constituents).

Special thanks to A.S.P.E.N., who also endorses HR 3839, for their assistance authoring this article.

2-Feb-12 3:30 PM

FDA Approval of ONFI™ (clobazam) for Adjunctive Therapy for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Thu, 02 Feb 2012 21:00:00 GMT

On October 21, 2011, the FDA approved ONFI™ (clobazam) as an adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years of age. Clobazam is an antiepileptic drug of the benzodiazepine class. It has been approved in other countries since the late 1970’s for the treatment of anxiety and epilepsy, and received Orphan drug designation on December 18, 2007, for the treatment of LGS in the U.S.

The effectiveness and safety of ONFI for the adjunctive treatment for LGS was evaluated in two controlled studies in about 300 patients with LGS. The exposure-response analysis of these data indicated that there are clear exposure-response relationships for both efficacy and safety. All three studied dose groups (10 mg, 20 mg, and 40 mg per day) were statistically significantly superior to the placebo groups with regard to the drop seizure rates, the primary efficacy endpoint. This effect was dose-dependent manner, with the greatest mean seizure reduction observed at the highest studied dose of 40mg/day. Sedation-related adverse events (i.e., sedation, somnolence, sleepiness, drowsiness, lethargy and listlessness) were the most common adverse reactions. Results showed that patients assigned to doses greater than 5 mg/day experienced a higher percentage of sedation-related adverse events than the placebo group. However, no significant difference between 20 mg/day and 40mg/day doses was observed.

ONFI should be administered in divided doses twice daily (the 5 mg dose can be administered as a single daily dose) and should be dosed according to body weight. Within each body weight group, dosing should be individualized based on clinical efficacy and tolerability. Dose escalation should not proceed more rapidly than weekly, because serum concentrations of clobazam and its active metabolite require 5 and 9 days, respectively, to reach steady-state.

Table 1. Recommended Total Daily Dosing by Weight Group

	≥30 kg Body Weight	>30 kg Body Weight
Starting Dose	5 mg	10 mg
Starting Day 7	10 mg	20 mg
Starting Day 14	20 mg	40 mg

Clobazam is extensively metabolized in the liver, with 82% of the administered dose recovered in urine (2% unchanged) and 11% in feces (1% unchanged). The major metabolic pathway of clobazam involves N-demethylation, primarily by CYP3A4 and to a lesser extent by CYP2C19 and CYP2B6. N-desmethylclobazam, known to have intrinsic benzodiazepine like activity, is the major circulating metabolite in humans, and its plasma concentrations are 3-5 times higher than those of clobazam. This metabolite is further metabolized by CYP2C19. In CYP2C19 poor metabolizers, levels of N-desmethylclobazam were 3-5-fold higher than that in CYP2C19 extensive metabolizers. In healthy adults and patients, the mean terminal half-life of clobazam (t_1/2) is 36 to 42 hours. The mean terminal half-life of N-desmethylclobazam is 71 to 82 hours.

Clobazam is an inhibitor of CYP2D6; thus, drugs metabolized by CYP2D6 may require dose adjustment when used with Onfi. Clobazam is a mild inducer of CYP3A4; dose adjustments are unnecessary for most 3A4 substrates considering the relatively small inducing effect. However, the effectiveness of some hormonal contraceptives metabolized by CYP3A4 may be diminished when given with ONFI. Additional non-hormonal forms of contraception are recommended when using ONFI.

Because the active metabolite N-desmethylclobazam is primarily metabolized by CYP 2C19, dosage adjustment is recommended when strong and moderate CYP2C19 inhibitors are used concomitantly with ONFI.

CYP3A4 inducers (phenobarbital, phenytoin, and carbamazepine), CYP2C9 inducers (valproic acid, phenobarbital, phenytoin, and carbamazepine), and CYP2C9 inhibitors (felbamate and oxcarbazepine) had no significant impact on the pharmacokinetics of clobazam and N-desmethylclobazam.

Dosing adjustments (i.e., starting dose at 5 mg/day, then be titrated according to weight, but to half the dose presented in Table 1 as tolerated; if necessary and based upon clinical response, an additional titration to the maximum dose [20 mg/day or 40 mg/day, depending on weight] may be started on day 21) are recommended for the following specific populations:

Geriatric patients had slower clobazam clearance, thus dosing adjustment is recommended.
CYP2C19 poor metabolizers had approximately 3- to 5-fold higher N-desmethylclobazam exposure (Cmax and AUC), compared to extensive metabolizers, respectively, with insignificant change in exposure to the parent drug. Dosing adjustment is recommended for patients who are known to be CYP2C19 poor metabolizers.
Clobazam is primarily metabolized in the liver. Dosing in patients with hepatic impairment should be adjusted for mild and moderate hepatic impairment patients. No dosing recommendation can be provided for patients with severe hepatic impairment because of inadequate data.

The exposure (C_max and AUC) of clobazam and N-desmethylclobazam were not significantly increased with mild and moderate renal impairment in a dedicated study; therefore, no dosing adjustment is recommended for patients with mild and moderate renal impairment. There is no experience with ONFI in patients with severe renal impairment or end stage renal disease (ESRD). It is not known if clobazam or N-desmethylclobazam is dialyzable.

Full prescribing information is available at:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202067s000lbl.pdf

By Ta-Chen Wu, Senior Clinical Pharmacologist, Angela Yuxin Men, Team Leader, Division of Clinical Pharmacology 1, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA

2-Feb-12 3:00 PM

Pharmacogenetic changes to the FDA-approved PLATINOL® (cisplatin) label include safety update regarding cisplatin-induced hearing loss in children

Thu, 02 Feb 2012 21:00:00 GMT

The FDA updated the PLATINOL^® (cisplatin) product label on December 29, 2011 to include new safety information pertaining to the association of variants in the thiopurine S-methyltransferase (TPMT) gene and an increased risk of cisplatin-induced ototoxicity in children. Cisplatin was originally approved as PLATINOL^® by the FDA in 1978 and is currently indicated for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.

Cisplatin’s toxicity profile includes risk for ototoxicity. Ototoxicity is manifested by tinnitus and high-frequency hearing loss which is often bilateral, typically irreversible, and can be progressive despite cessation of cisplatin. Hearing loss can occur following a single cisplatin dose, but tends to become more frequent and severe following repeated dosing. Ototoxic effects may be related to peak plasma concentrations of cisplatin. While cisplatin-induced ototoxicity can occur in both adults and children, its prevalence in children is estimated to be as high as 60% and the ototoxic effects can be particularly devastating on a child’s cognitive, speech, language, and socio-emotional development.

A retrospective study¹ involving an initial cohort and a replicative cohort totaling 162 children who received conventional doses of cisplatin revealed an association between variants in the TPMT gene (e.g., TPMT*3B and TPMT*3C) and an increased risk of cisplatin-induced hearing loss (Odds Ratio of 17.0 [95% CI 2.3-125.9]). Patients were administered a median cumulative cisplatin dose of 400 mg/m² for a median treatment duration of 4-5 weeks. Although only 26 of the 162 patients (16%) had one or more TPMT gene variants, 25 of the 26 (96%) developed severe ototoxicity. For Caucasians and African Americans, approximately 11% of the population inherit one or more of these TPMT variants. Children who do not have one of these TPMT gene variants remain at risk for ototoxicity. Other genetic factors may also contribute to cisplatin-induced ototoxicity.

The updated label is expected to inform healthcare providers about the association between genetic factors and cisplatin-induced ototoxicity in children and to stress the importance of monitoring and management strategies for hearing loss. The label recommends that all children receiving cisplatin should have audiometric testing at baseline, prior to each subsequent dose of drug, and for several years post therapy. The use of advanced audiometric testing methods may allow for earlier detection of hearing loss and rapid initiation of interventions that can limit the potential adverse impact of hearing impairment on a child’s cognitive and social development.

Full prescribing information is available at:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s081lbl.pdf

By Dionna Green, M.D., Pediatric Clinical Pharmacologist, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA

Ross, C.J., Katzov-Eckert H., et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving Cisplatin chemotherapy. Nat. Genet.2009;41:1345-1349.

2-Feb-12 3:00 PM

2012 Call for Board Nominations

Matthew Helms - noemail@ppag.org — Wed, 18 Jan 2012 16:45:00 GMT

Deadline: February 17, 2012

The PPAG Board of Directors is requesting nominations for President-Elect, Secretary, Treasurer, and three (3) at-large Board positions that will begin April 2012.

President-Elect:

The President of the organiation presides over all meetings of the membership and Board of Directors. The President is the official spokesperson of PPAG, and makes a report of his/her administration at the Annual Conference and make recommendations deemed necessary. The President-Elect performs these duties in the absence of the President and will become President at the end of the term.

To be eligible to serve as President-Elect, a candidate must be a current or previous Director of PPAG.

Secretary:
The Secretary attests all documents of the organization, reviews and updates policies and procedures manual, and services as ex-officio member of any governing task force.

To be eligible to serve as Secretary, a candidate must be a current or previous Director of PPAG.

Treasurer:

The Treasurer chairs the Finance Committee, reviews monthly financial statements, and develops and monitors the Annual Budget.

To be eligible to serve as Treasurer, a candidate must be a current or previous Director of PPAG.

At-Large Director: Three (3) positions:

To be eligible as a candidate for a Board of Director position the following criteria apply:

Be a member of PPAG in good standing for at least three years
Be committed to attend all Board Meetings and conference calls (one in-person meeting)
Actively participate throughout the year
Support the mission, vision, values, and goals of PPAG.
Candidate has made contributions to the practice of pediatric pharmacy.

Board member responsibilities include, but are not limited to:

Attend the one in-person Board meeting and participate in at least four conference calls each year as specified in the bylaws
Attend activities, special events, Board retreats, and general membership meetings
Fairly consider other points of view, make constructive suggestions, reach consensus, and help the Board make decisions that benefit children, PPAG members, or others served by the PPAG mission
Assume Board leadership roles
Represent and promote PPAG to individuals, the public, Industry and other organizations
Actively participate in the fundraising efforts of the organization
Coverage of individual travel and meeting attendance costs

Any member of PPAG may nominate an individual, including oneself.

The deadline for submitting nominations is February 17, 2012, 12:00 midnight (eastern time).

Submit all nominations electronically to Matthew Helms, Executive Director of PPAG. Please include name, contact information, and a brief summary of why you feel this person will make a qualified member of the Board of Directors. Send nominations to: Matthew.helms@ppag.org.

18-Jan-12 10:45 AM

Renew and Recruit: A Letter from the PPAG President

Dave Knoppert - noemail@ppag.org — Fri, 13 Jan 2012 03:00:00 GMT

Dear PPAG Members and Friends,

When the Board of Pharmacy Specialties (BPS) announced that they would conduct a Role Delineation Study for Pediatrics a few months ago, we all became quite excited. BPS subsequently announced the members of the Pediatric Specialty Task Force, most of whom are PPAG members, and that process has begun.

However, many of you still wish to help in some way. During the past few weeks we have received questions about this at PPAG. Many of you have asked "What I can do to help with the Board Certification process?" Our answer may have been somewhat disappointing to you: “there is not much more we can do than wait”. However, there IS something tangible (and easy) that you can do.

The decision to approve a Board Certified Specialty is based on many factors. Proving that there is a critical mass of individuals interested in taking the Certification Exam is extremely important. PPAG survey data suggest that over 1,500 people would be interested in taking the exam. But surveys are only one way to measure interest.

Another way to gauge interest in specialty certification is participation in professional pharmacy associations like PPAG. Indeed, the number of PPAG members and the number of pediatric practitioners within ASHP and ACCP are vitally important factors to BPS.

So, what can YOU do? Keep your membership up-to-date and make sure that you renew it. Encourage your Pediatric colleagues to join PPAG. Discuss with them why Board Certification is important to Pediatric Pharmacy.

There IS something that we can ALL do to help. I encourage each and every one of you to do these simple things that I have suggested above. If each of us does this then we will help increase the critical mass of Pediatric Pharmacists that is so important to the certification process.

If you have any questions or suggestions please feel free to contact me or any member of the Board of PPAG.

Best regards,

David Knoppert, MScPhm
President
PPAG
2011-12

12-Jan-12 9:00 PM

Pfizer Fesoterodine Study

Edress Darsey - noemail@ppag.org — Fri, 13 Jan 2012 02:00:00 GMT

Pfizer is setting up a clinical study in the US to investigate fesoterodine in children aged 6 to 16 years old with neurogenic detrusor overactivity (NDO).

The purpose of the study is to characterize the effects of fesoterodine in that population, more specifically on wetting episodes, catheterizations or frequency of passing urine, and bladder function, as well as the side effect profile, as it has not yet been approved in that population. A comparison with oxybutynin XL will be incorporated.

If you require further details, and/or know of any physicians and research centres who might be interested in participating in the study, please contact Edress Darsey at edress.darsey@pfizer.com or 404-386-0516.

Thank you.

12-Jan-12 8:00 PM

2012 Call for Abstracts

Matthew Helms - noemail@ppag.org — Thu, 08 Dec 2011 20:00:00 GMT

General Information
February 24, 2012 for Practice-based and Scientific Abstracts
March 30, 2012 for Residency Project Abstracts

All practitioners, investigators, and post-doctoral trainees in the field of pediatric clinical pharmacy, whether members of PPAG or not, are invited to submit abstracts of papers to be considered for platform or poster presentation at the 21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference. The conference will be held at the Houston Marriott at the Texas Medical Center in Houston, TX. Poster and Platform Presentations will be held on Friday, April 20, 2012.

All research and practice abstracts should be no longer than 450 words. Research abstracts will be published in the Journal of Pediatric Pharmacology and Therapeutics. Platform Presentations and Best Practice Awards will be chosen from the abstracts submitted.

There are two tracks for abstract submissions:

Research/Scientific Track: February 24, 2012 deadline
Practice Based Track: February 24, 2012 deadline
Residency Project Track: March 30, 2012 deadline

Submit Abstract Here

Research/Scientific Track

Research abstracts presented at PPAG report the results of a scientific investigation or a clinical observation (case report) involving some aspect of pharmacotherapy. Scientific investigations can be either clinical, basic, or translational and are either hypothesis-driven or descriptive in nature. To be accepted for presentation, research abstracts must have either preliminary or final results. Abstracts without results will not be accepted in this category. The abstract may be submitted in any of the following categories: Scientific, Case Report, and Encore Presentations (a poster that has been presented and published elsewhere. The original citation must accompany encore presentations).

For useful tips in drafting your abstract, please visit: Guidelines for Abstract Preparation.

All submissions will be eligible for the Young Investigator or Best Original Paper awards. The finalists will be judged by a panel of judges during the poster and platform presentation sessions. Primary authors may be considered for all awards for which they are eligible, but may win only one award.

Outstanding Original Paper

Outstanding Original Paper Investigators will be evaluated on the basis of their written abstract and the quality of their presentation at the Meeting. The winner will receive complimentary registration to next year's Annual Meeting and a framed certificate.

Christensen Memorial Young Investigator Award

PPAG Young Investigator Award is available to investigators who have been in practive five (5) years or less . This award will be granted to the investigator based on their written abstract and the quality of their presentation at the Meeting.

Deadline February 24, 2012

Submit Abstract Here

Best Practice Track

Best and Innovative Pediatric Pharmacy Practice Abstracts typically describe programs, systems, or projects that are innovative, creative, cost-effective, and improve practice in pediatric pharmacy. BPA/IPPP Posters will be selected based on achievement of excellence in each of the four areas.

Winners of the Best Practice Award will be chosen from accepted abstracts. The program, system, or project can be an individual or collaborative effort in any type of practice setting, including academia, institutional, or ambulatory care. Unlike Research Abstracts, Best Practice Abstracts are not required to have final or preliminary data, but should include sufficient details about the rationale, process, and hypothesis of the impact should the program, system, or project be implemented. Accepted abstracts will be published in the Journal of Pediatric Pharmacology and Therapeutics.

Submissions should include any pictures, graphs, figures and data tables that supports the summary. Each of these must be clearly labeled and described.

Lexi-Comp Best Practice Awards

PPAG will award up to two (2) Best Practice Awards during the 21st Annual Meeting in Houston, TX. The awards are given to innovative and creative pharmacy programs that advance the mission, vision, and goals of the organization. Recipients of the award receive a plaque for the practice site and a certificate recognizing each contributor to the program. Award recipients will share their best practice during a presentation at the Annual Meeting and as a poster at the Annual Meeting.

The Best Practice Awards are generously supported by Lexi-Comp.

Deadline February 24, 2012

Submit Abstract Here

Residency Project Presentations and Showcase

Each year the Pediatric Pharmacy Advocacy Group offers an opportunity for Post-doctoral trainees (Residents and Fellows) to present their projects to pediatric pharmacy practitioners from across North America.

Residents will be able to present their projects during the Bruce Parks Memorial Showcase on Thursday, April 19, 2012 or Saturday, April 21, 2012 during the 21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference.

Presentations will be limited to 10 minutes in length. The format for the presentations is similar to the format used at regional residency conferences. Presentations can be on any pediatric-based project and may be a work-in-progress.

Abstracts can be no longer than 450 words in length. For useful tips in drafting your abstract, please visit: Guidelines for Abstract Preparation.

Deadline March 30, 2012

Submit Abstract Here

8-Dec-11 2:00 PM

Local Community Spotlight: Gateway Pediatric Pharmacy Group

Mon, 05 Dec 2011 14:00:00 GMT

The Gateway Pediatric Pharmacy Group (GPPG), a local community of PPAG, held its very first meeting in November 2010. GPPG has been busy ever since with every other month meetings rotating locations between the four major pediatric institutions around St. Louis. These include:

St. Louis Children’s Hospital
Cardinal Glennon Children’s Medical Center
Mercy Children’s Hospital
Ranken Jordan

Dr. Brandy Bratcher was elected to serve as the inaugural local coordinator along with four institutional representatives. Not only did Brandy include time within meeting agendas for discussion on the hot topics (i.e. drug shortages), but she also organized accredited continuing education through PPAG for most meetings. More importantly, GPPG replaced one meeting with fundraising and participated as a group in our local ‘Cure Search’ walk. GPPG raised over $1,000 for the Children’s Oncology Group.

Dr. Bratcher stated, "We believe we have really met our group’s goal this past year of ‘connecting pediatric pharmacists that serve in the Greater Saint Louis area by providing networking opportunities, an avenue to exchange ideas and best practices, and volunteer and leadership opportunities’. We look forward to expanding our group to local pharmacy students from the Southern Illinois University Edwardsville School of Pharmacy and the St. Louis College of Pharmacy."

What a great year for pediatric pharmacy in St. Louis!

5-Dec-11 8:00 AM

PPAG Unveils New Journal Website

Matthew Helms - noemail@ppag.org — Mon, 28 Nov 2011 22:00:00 GMT

The Pediatric Pharmacy Advocacy Group has unveiled a new website for the Journal of Pediatric Pharmacology and Therapeutics (JPPT). The new journal site offers abstract view, full-text views, article sharing and exporting, and citation tracking.

Individual subscribers and members of PPAG have individual access to the Journal. If you are a member you must register on the site.

The new site also offers institutional subscriptions for hospitals, libraries and universities. Through an insitutional subscription, all individuals within an institution can access Journal content for free (within the local network). Please contact PPAG for more information.

Please visit the new website at http://www.jppt.org.

We are working on our archive. Soon, volumes 8 through volume 16 will be available on the site and PubMedCentral.

The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy.

The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues.

The Journal contains original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.

28-Nov-11 4:00 PM

Pharmacist - Children''s Hospital at Montefiore

Thu, 26 Jan 2012 06:00:00 GMT

Title: Pharmacist - Children''s Hospital at Montefiore Description: Here at Montefiore Medical Center it is our vision to transform health and enrich the lives of everyone we care for. But it doesn't stop there; we also take pride in the fact that the same dedication we deliver to our patients is also given to our employees. By providing our staff with extensive clinical education, training programs and graduate medical education we have become one of the most prestigious healthcare systems in the nation. We are currently seeking Pharmacists to become part of our extraordinary team at the Children's Hospital at Montefiore (CHAM). The Children's Hospital at Montefiore (CHAM) is one of the nation's top-ranked pediatric hospitals, committed to providing care that transforms the health of children. By combining supreme clinical expertise, cutting-edge technology and outstanding medical education, CHAM has earned distinction as one of America's Best Children's...

Newly Endowed Professor in Outcomes Research

Mon, 23 Jan 2012 06:00:00 GMT

Title: Newly Endowed Professor in Outcomes Research Description: Texas Tech University Health Sciences Center School of Pharmacy and its Pediatric Pharmacology Research and Development Center (PPRDC) announce a newly endowed Professor in Outcomes Research. Individuals, eligible for appointment at the Associate and Full Professor rank, with an interest in pediatric drug research and development are encouraged to apply. Enabled by generous funding from the James A. Buddy Davidson Charitable Foundation, the Endowed Professor will work with a dedicated Pediatrics Division in the School, as well as Dallas-based hospital and university partners. The PPRDC currently provides sophisticated analytical, pharmacokinetic/pharmacodynamic and clinical study design support to TTUHSC and the University of Texas Southwestern (UTSW). Addition of an outcomes research unit will expand and synergize with these already successful investigators. The James A. Buddy Davidson Charitable...

Pharmacy Clinical Specialist

Wed, 18 Jan 2012 06:00:00 GMT

Title: Pharmacy Clinical Specialist Description: Connecticut Children's Medical Center is a nationally recognized leader in pediatric care and the region's only academic medical center devoted exclusively to the care of children. Connecticut Children's Medical Center offers a full range of services for children from birth through age 18 and provides quality care through 10 affiliated community hospitals and 15 practice locations. Pharmacy Clinical Specialist Ensures optimal drug therapy for complex patients and conducts educational and research activities to promote high quality, safe and cost effective patient care. Requirements: Advanced degree in pharmacy such as Pharm.D or Masters degree in Pharmacy Practice. Connecticut Pharmacist license, and 3-5 years pharmacy experience is required. Connecticut Children's Medical Center offers excellent benefits including on-site child care, educational assistance, free parking, paid time-off, and more. ...

Clinical Pharmacists (START DATE 08/2012)

Fri, 13 Jan 2012 06:00:00 GMT

Title: Clinical Pharmacists (START DATE 08/2012) Description: At Nemours, we're dedicated to achieving higher standards in children's health. And we begin by caring for every child as if they were our own. For more than 70 years, this has been the Nemours Way. Nemours began with the vision of Alfred I. duPont to improve the lives of children. Today, our team of 4,200 dedicated Associates, including more than 420 pediatric physicians, has cared for millions of kids. But it's the special way we care that's made Nemours a trusted choice for families across the country. We're more than a children's hospital. As one of the nation's leading pediatric health care systems, Nemours delivers care differently. We've made a promise to do whatever it takes to prevent and treat even the most disabling childhood conditions. It's a promise that extends beyond our nationally recognized clinical care to an entire integrated spectrum of research, advocacy, education and prevention services...

Clinical Pharmacy Specialist - Emergency Department (START DATE 08/2012)

Thu, 12 Jan 2012 06:00:00 GMT

Title: Clinical Pharmacy Specialist - Emergency Department (START DATE 08/2012) Description: At Nemours, we're dedicated to achieving higher standards in children's health. And we begin by caring for every child as if they were our own. For more than 70 years, this has been the Nemours Way. Nemours began with the vision of Alfred I. duPont to improve the lives of children. Today, our team of 4,200 dedicated Associates, including more than 420 pediatric physicians, has cared for millions of kids. But it's the special way we care that's made Nemours a trusted choice for families across the country. We're more than a children's hospital. As one of the nation's leading pediatric health care systems, Nemours delivers care differently. We've made a promise to do whatever it takes to prevent and treat even the most disabling childhood conditions. It's a promise that extends beyond our nationally recognized clinical care to an entire integrated spectrum of research, advocacy,...

Clinical Pharmacy Specialist - Hematology/Oncology/IDS (START DATE 08/2012)

Thu, 12 Jan 2012 06:00:00 GMT

Title: Clinical Pharmacy Specialist - Hematology/Oncology/IDS (START DATE 08/2012) Description: At Nemours, we're dedicated to achieving higher standards in children's health. And we begin by caring for every child as if they were our own. For more than 70 years, this has been the Nemours Way. Nemours began with the vision of Alfred I. duPont to improve the lives of children. Today, our team of 4,200 dedicated Associates, including more than 420 pediatric physicians, has cared for millions of kids. But it's the special way we care that's made Nemours a trusted choice for families across the country. We're more than a children's hospital. As one of the nation's leading pediatric health care systems, Nemours delivers care differently. We've made a promise to do whatever it takes to prevent and treat even the most disabling childhood conditions. It's a promise that extends beyond our nationally recognized clinical care to an entire integrated spectrum of research, advocacy,...

Clinical Pharmacy Specialist - Pediatric/Neonatal Intensive Care (START DATE 08/2012)

Thu, 12 Jan 2012 06:00:00 GMT

Title: Clinical Pharmacy Specialist - Pediatric/Neonatal Intensive Care (START DATE 08/2012) Description: At Nemours, we're dedicated to achieving higher standards in children's health. And we begin by caring for every child as if they were our own. For more than 70 years, this has been the Nemours Way. Nemours began with the vision of Alfred I. duPont to improve the lives of children. Today, our team of 4,200 dedicated Associates, including more than 420 pediatric physicians, has cared for millions of kids. But it's the special way we care that's made Nemours a trusted choice for families across the country. We're more than a children's hospital. As one of the nation's leading pediatric health care systems, Nemours delivers care differently. We've made a promise to do whatever it takes to prevent and treat even the most disabling childhood conditions. It's a promise that extends beyond our nationally recognized clinical care to an entire integrated spectrum of research,...

Pediatric Pharmacotherapy Faculty Position

Wed, 11 Jan 2012 06:00:00 GMT

Title: Pediatric Pharmacotherapy Faculty Position Description: Pediatric Pharmacotherapy Faculty Position Department of Pharmacy: Clinical and Administrative Sciences - Tulsa The University of Oklahoma College of Pharmacy Tulsa, Oklahoma The University of Oklahoma College of Pharmacy invites applicants for a non-tenure track appointment in pediatric pharmacotherapy to continue development of pharmaceutical care services to patients of OU Physicians Pediatrics in Tulsa. Services will be accomplished in conjunction with the OU Department of Pediatrics. Opportunities exist in outpatient clinics including asthma, behavioral medicine, endocrinology, and general pediatrics. Responsibilities include development and provision of patient care services, research and scholarship, and experiential training of doctor of pharmacy students, pharmacy practice and specialty residents. Responsibilities also inlcude supporting the College of Pharmacy mission and goals through...

ASSISTANT/ASSOCIATE PROFESSOR - PEDIATRICS

Wed, 14 Dec 2011 06:00:00 GMT

Title: ASSISTANT/ASSOCIATE PROFESSOR - PEDIATRICS Description: POSITION SUMMARY The University of Maryland, Baltimore campus seeks an Assistant/Associate Professor (Tenure or Non-Tenure Track) in the Department of Pharmacy Practice and Science. This position requires teaching, practice, service to the school, campus and the profession, and scholarly activity as a pediatric specialist. The position is a full-time, 12 month appointment. In addition to practice, service, and scholarly activity as a pediatric specialist, this faculty member will provide leadership in their area of specialty and will provide clinical services at the University of Maryland Medical Center. SUPERVISORY CONTROLS This position is responsible to the Chair of the Department of Pharmacy Practice and Science with additional clinical reporting responsibility to the medical/pharmacy director or designee at the practice site. Required Experience: MINIMUM QUALIFICATIONS An earned...

Key Issues

Fri, 03 Feb 2012 18:55:38 GMT

Reauthorization of Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) BPCA and PREA have changed pediatric practice because all studies result in labeling changes that provide valuable new pediatric information. These studies have resulted in new dosing information, new indications of use, new safety information, and new data on effectiveness. Drugs studied under BPCA and PREA treat a wide range of diseases in children, including cancer, HIV/AIDS, diabetes, allergy and asthma. 426 drug labels have been revised with important pediatric information (181 under PREA, 147 under BPCA, 50 under both BPCA and PREA, and 48 under precursor regulations). Before BPCA and PREA, the vast majority of drugs-more than 80%-used in children were used off-label, without data on their safety or efficacy. Today that number has been reduced to approximately 50%. While there has been significant success, more progress is needed. PPAG endorses the...

21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference AGENDA

Thu, 26 Jan 2012 19:39:12 GMT

The Conference features two educational blocks. Infectious Diseases will be the focus of the Conference April 18-20, 2012. The Conference also offers a look at Clinical Leadership and Management in Pediatric Pharmacy from April 20-22, 2012 Infectious Diseases The ID Block features two educational tracks: (1) Review and (2) Advanced. Level 1 programs provide a review of current practices in the topic identified and are appropriate for both new practitioners and those seeking to update their knowledge base. Level 2 programs provide an advances review of the identified optic and new developments in the field. Level 2 programs are appropriate for the advanced level practitioner. Infectious Disease Key Review Advanced WEDNESDAY, April 18, 2012 Infectious Diseases Block 8am - 4pm Registration ...

Fellow in the Pediatric Pharmacy Advocacy Group (FPPAG)

Mon, 02 Jan 2012 18:24:49 GMT

Purposes The Fellow in the Pediatric Pharmacy Advocacy Group (FPPAG) Recognition Program serves the following purposes: 1. to recognize excellence in pediatric pharmacy practice; 2. to grant recognition and to promote public awareness of pharmacists who have distinguished themselves in pediatric pharmacy practice. Authority The FPPAG Recognition Program shall be conducted under the general authority of the PPAG Board of Directors. The Board shall approve all regulations pertaining to the operation of the Recognition Program. Governance FPPAG Recognition Committee: Function and Responsibilities The program shall be administered by the FPPAG Recognition Committee, which shall be appointed by the Board of Directors, and shall have the following specific responsibilities, with respect to the FPPAG Program: to review and approve recognition eligibility criteria and, in general, to provide quality assurance for the program; ...

Membership Thank You

Mon, 02 Jan 2012 17:59:41 GMT

Thank you for joining the Pediatric Pharmacy Advocacy Group. Please consider making a tax-deductible donation to PPAG. Go to: http://www.ppag.org/en/donations/add.asp for more information. To view the member-only section of the website, direct your browser to: http://www.ppag.org/en/users/. You may want to check out these features and programs, too: PPAG Annual Meeting and Pediatric Pharmacy Conference Online Continuing Education Programs Webinar Continuing Education Programs The Journal of Pediatric Pharmacology and Therapeutics Pediatric Pharmacy Advocate eNewsletter PediNet, Email Communities JobCentral, Career Opportunities PPAG Bookstore Artemis Medication Safety Initiative Advocacy efforts Local Communities and Networks Again, thank you. Please use the...

Association Staff

Mon, 21 Nov 2011 20:57:18 GMT

Matthew R. Helms, MA, CAE
Executive Director

Matthew Helms has been the Executive Director of the Pediatric Pharmacy Advocacy Group since 2003. Matt earned his Bachelor of Arts degree in political science (history minor) from The University of Tennessee, Knoxville in 1998. He earned Master of Arts in Executive Leadership from Christian Brothers University in Memphis, Tennessee in 2009. Matt earned the Certified Association Executive (CAE) credential in 2009.

Matt directs all day-to-day operations of PPAG. He provides direction and policy interpretation to volunteer leadership. He manages all aspects of membership services, develops new services, coordinates continuing education programs, and solicits sponsorships, grants, and donations.

Since 2004 Matt has been a member of the ASAE & The Center for Association Leadership, as well as, the Tennessee Society of Association Executives. He serves on the TSAE Board of Directors. Matt also serves on the Board of Memphis Challenge. In 2011, he was appointed to the Shelby County (Tennessee) Head Start Policy Advisory Council.

Neonatal Pharmacy Resident/Fellow Research Grant

Thu, 17 Nov 2011 20:37:40 GMT

Supported by Lundbeck, Inc. Application Deadline: September 15 each year. Pediatric Pharmacy Advocacy Group is an international, nonprofit, professional association representing the interests of pediatric pharmacists and their patients. We are dedicated to improving medication therapy in children. Our sole purpose is to promote safe and effective medication use in children through communication, education, and research. Purpose The Neonatal Pharmacy Resident/Fellow Research Grant supports research in neonatal medication use conducted by pharmacy residents (e.g., PGY-1, PGY-2 pediatric pharmacy resident) and fellows. The primary purpose of the research award is to improve safe and effective use of medications in neonates. Research projects can comprise a wide range of medication-use topics, including but not limited to: technology, safety, and/or pharmacotherapy. A secondary goal of the program is to develop and strengthen the skills of pharmacy residents...

Homepage2

Tue, 11 Oct 2011 15:49:14 GMT

Improve your knowledge base from anywhere! We offer online and live webinar continuing pharmacy education programs. You can earn CE from the comfort of your home or office. PPAG member receive a pricing discount on all courses offered. ONLINE COURSE LISTINGS || WEBINAR COURSE LISINGS Featured Online Education Programs: Core Competencies for Pediatric Pharmacists. Featured Webinars: To be announced. What YOU can do for PPAG! PPAG believes in the value of every members expertise and passion. We are a member-driven organization, and those members make the difference!...

homepage - conference info

Wed, 05 Oct 2011 20:02:47 GMT

21th PPAG Annual Meeting and
Pediatric Pharmacy Conference

Houston Marriott at the Texas Medical Center

Houston, Texas

April 18-22, 2012

Education Program Evaluation Confirmation

Thu, 29 Sep 2011 17:25:06 GMT

Thank you participating in a PPAG educational event and for submitting your education program evaluation. We hope you enjoyed your experience.

Continuing education certificates will be sent to you via email in 1-2 weeks.

Thank you.

Richard A. Helms Award of Excellence

Fri, 23 Sep 2011 20:05:30 GMT

The Richard A. Helms Award of Excellence in Pediatric Pharmacy Practice was establised in 2006 by the Pediatric Pharmacy Advocacy Group Board of Directors. The Helms Award recognizes (1) sustained and meritorious contributions to PPAG and to pediatric pharmacy practice, and (2) contributions of importance to education, new knowledge, and outreach. The Richard A. Helms award is made possible by the generous donations of colleagues, friends, and past postdoctoral trainees of Dr. Helms. To be eligible for the award, nominees should be a practitioner who has made a lasting contribution to pediatric pharmacy practice. Nominees must be in pediatric pharmacy practice for a minimum of fifteen (15) years and an active member of PPAG for a minimum of five (5) continuous years. About Dr. Richard A. Helms For over 30 years, Dr. Helms has been instrumental in defining the standard of practice in pediatric parenteral nutrition. His commitment to the care of children is...

Pediatric Pain Management Webinar

noemail@ppag.org — Mon, 23 Jan 2012 20:00:00 GMT

Objectives:

To evaluate the effectiveness of the educational session, speaker, educational format, and educational delivery.

Release Date: 23-Jan-12 2:00 PM
Expiration Date: 8-Feb-12 11:00 PM

Please fill out the form by February 8, 2012 (midnight eastern time)

MRSA: What do you do when you can't use Vancomycin?

noemail@ppag.org — Tue, 27 Sep 2011 16:00:00 GMT

Objectives:

To evaluate the effectiveness of the educational session, speaker, educational format, and educational delivery.

Release Date: 27-Sep-11 11:00 AM
Expiration Date: 6-Oct-11 3:00 AM

Please fill out the form by October 5, 2011.

Evaluation of Pediatric Aged-Based Competency: Anatomic and Physicologic Differences Between Childre

noemail@ppag.org — Thu, 21 Apr 2011 18:45:00 GMT

Objectives:

The goal of this survey is to evaluate the qualify and effectiveness of online course content.

Release Date: 21-Apr-11 1:45 PM
Expiration Date: 20-Jul-11 1:45 PM

You will be asked to read a series of statements. Please indicate if you strongly agree, somewhat agree, strongly disagree, somewhat disagree, or are neutral.

Acthar Gel (repository corticotrophin injection) Survey

noemail@ppag.org — Mon, 26 Feb 2007 17:00:00 GMT

Objectives:

This is a survey for pharmacies that order Acthar Gel (repository corticotrophin injection). The product is currently indicated for the treatment of acute exacerbations of multiple sclerosis and other conditions, and it is used off-label for treatment of infantile spasms. The maker of Acthar Gel, Questcor, filed a supplemental new drug application for the infantile spasms indication in August 2006. The company is now trying to understand how much of Acthar Gel usage is for multiple sclerosis and how much is for infantile spasms.

PPAG has received a small grant to conduct this survey.

Release Date: 26-Feb-07 11:00 AM
Expiration Date: 10-Apr-07 4:00 PM

if you use Acthar Gel, please fill out the survey to the best of your ability. Please coordinate within your institution so we do not receive duplicate information. We are not asking for facility name or participant information (involuntarily) in order to ensure confidentiality.

Medication Administration in Schools

noemail@ppag.org — Wed, 12 Jul 2006 19:00:00 GMT

Objectives:

We are looking to identify challenges and or cases within local school system or daycare settings.

For example: "Johnny’s" school doesn’t have a nurse, the school refuses to allow any medication administration, and so a parent goes to school everyday to administer!

The results of this survey will be presented at the 15th Annual Meeting during the Advocacy Workshop.

Release Date: 12-Jul-06 2:00 PM
Expiration Date: 10-Sep-06 2:00 PM
Please read and respond to the following questions.

What are your thoughts about PediNet?

noemail@ppag.org — Tue, 08 Nov 2005 15:00:00 GMT

Objectives: The Membership Services Committee values your opinion about the services PPAG provides its members. This survey was created to get your feedback about our PediNet Member Forums.

Release Date: 8-Nov-05 9:00 AM
Expiration Date: 14-Apr-06 9:00 AM
Please answer the questions provided. There are only 8 questions to answer. It should not take that long to complete.

2006-07 Educational Needs Assessment

noemail@ppag.org — Thu, 06 Oct 2005 02:00:00 GMT

Objectives: To better understand the continuing educational needs of our members.

Release Date: 5-Oct-05 9:00 PM
Expiration Date: 3-Jan-06 9:00 PM

Please offer comments in the text boxes provided.

Antifungal Survey for Stem Cell Transplantation/ Hematology-Oncology

noemail@ppag.org — Thu, 30 Jun 2005 21:00:00 GMT

Objectives:

To evaluate the use of antifungal agents in the pediatric hematology-oncology (H/O) and 

stem cell transplant (SCT) population and to assess differences in practice among various 

institutions.

Release Date: 30-Jun-05 4:00 PM
Expiration Date: 30-Mar-06 4:00 PM
Please participate in the following survey. Any PPAG member or affiliate can take the survey. Please coordinate your response within your institution to avoid duplicity.

To climb steep hills, requires slow pace at first.

Tue, 21 Jun 2005 23:24:19 GMT

"To climb steep hills, requires slow pace at first."

William Shakespeare, Henry VIII

Core Competency Series: Pediatric Parenteral Nutrition

2010-03-19T13:00:00Z

Instructor: Kathleen Gura, PharmD

This program is a one hour Power Point presentation with synched audio. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the course handout (PDF), click here. After completion of the program, you may take the post-test to receive credit.

Extreme Dosing: Case Studies in Pediatric Transplantation

2010-03-19T13:00:00Z

Instructor: William McGhee

Extreme Dosing in Overweight/Obese Children - Focus on DVT Prophylaxis

2010-03-19T13:00:00Z

Instructor: Peter Johnson

Extreme Dosing in CF: Aminoglycosides

2010-03-19T13:00:00Z

Instructor: Heidi Smith Hoopingarner

Hot Topics in Pediatric ID, Critical Care, and Nutrition

2009-09-27T13:00:00Z

Instructor: Jeff Cies, PharmD and Betsy Walter, PharmD

This program is a two hour Audio presentation synced with PowerPoint slides. The program contains three sections. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF documents for each section, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Medication Use During ECMO and Continuous Renal Replacement Therapy

2009-09-26T13:00:00Z

Instructor: Brenda Dodson

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Community-Acquired MRSA in Pediatric Patients

2009-09-26T13:00:00Z

Instructor: Kristin Klein, PharmD

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Management of Pediatric Chemical Casualties: Are We Prepared

2009-09-25T13:00:00Z

Instructor: Elora Hilmas

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Adolescents, Sexuality, and The Pediatric Pharmacist

2009-09-25T13:00:00Z

Instructor: Veenod Chulani

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

Core Competency Series: Management of Diabetes Type 1

2009-09-24T18:00:00Z

Instructor: Michelle Condren

This program is a one hour Audio presentation synced with PowerPoint slides. To begin this program, please click the start icon below. You can follow along by downloading the handout below. To download the PDF document, please click the go button below. After completion of the program, you may take the post-test to receive credit.

PPAG RSS Feed

21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference on 18-Apr-12 8:00 AM

Conference Agenda Information

Call For Abstracts

Registration Information and Policy

Hotel Information-- Affordable Rates!

About Houston, Texas

22nd Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference on 1-May-13 8:30 AM

Conference Agenda Information

Call For Abstracts

Registration Information and Policy

Hotel Information-- Affordable Rates!

About Indianapolis, IN

PPAG Joins Coalition for BCPA/PREA

BPCA and PREA: An Overview

A Track Record of Success

Priorities for Reauthorization

PPAG Endorses Drug Shortages Prevention Act: Call to Action

FDA Approval of ONFI™ (clobazam) for Adjunctive Therapy for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Pharmacogenetic changes to the FDA-approved PLATINOL® (cisplatin) label include safety update regarding cisplatin-induced hearing loss in children

2012 Call for Board Nominations

Renew and Recruit: A Letter from the PPAG President

Pfizer Fesoterodine Study

2012 Call for Abstracts

Local Community Spotlight: Gateway Pediatric Pharmacy Group

PPAG Unveils New Journal Website

Pharmacist - Children''s Hospital at Montefiore

Newly Endowed Professor in Outcomes Research

Pharmacy Clinical Specialist

Clinical Pharmacists (START DATE 08/2012)

Clinical Pharmacy Specialist - Emergency Department (START DATE 08/2012)

Clinical Pharmacy Specialist - Hematology/Oncology/IDS (START DATE 08/2012)

Clinical Pharmacy Specialist - Pediatric/Neonatal Intensive Care (START DATE 08/2012)

Pediatric Pharmacotherapy Faculty Position

ASSISTANT/ASSOCIATE PROFESSOR - PEDIATRICS

Key Issues

21st Annual PPAG Meeting and 2012 Pediatric Pharmacy Conference AGENDA

Fellow in the Pediatric Pharmacy Advocacy Group (FPPAG)

Membership Thank You

Association Staff

Neonatal Pharmacy Resident/Fellow Research Grant

Homepage2

homepage - conference info

Education Program Evaluation Confirmation

Richard A. Helms Award of Excellence

Pediatric Pain Management Webinar

MRSA: What do you do when you can't use Vancomycin?

Evaluation of Pediatric Aged-Based Competency: Anatomic and Physicologic Differences Between Childre

Acthar Gel (repository corticotrophin injection) Survey

Medication Administration in Schools

What are your thoughts about PediNet?

2006-07 Educational Needs Assessment

Antifungal Survey for Stem Cell Transplantation/ Hematology-Oncology

To climb steep hills, requires slow pace at first.

Core Competency Series: Pediatric Parenteral Nutrition

Extreme Dosing: Case Studies in Pediatric Transplantation

Extreme Dosing in Overweight/Obese Children - Focus on DVT Prophylaxis

Extreme Dosing in CF: Aminoglycosides

Hot Topics in Pediatric ID, Critical Care, and Nutrition

Medication Use During ECMO and Continuous Renal Replacement Therapy

Community-Acquired MRSA in Pediatric Patients

Management of Pediatric Chemical Casualties: Are We Prepared

Adolescents, Sexuality, and The Pediatric Pharmacist

Core Competency Series: Management of Diabetes Type 1

Hotel Information--
Affordable Rates!

Hotel Information--
Affordable Rates!